Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven A Julious

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
BMC Public Health|June 7, 2014
A theory-based online health behaviour intervention for new university students (U@Uni): results from a randomised controlled trialTracy Epton, Paul Norman, Aba-Sah Dadzie, et al.
Trials|October 12, 2018
Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA<sup>2</sup> guidanceWilliam Sones, Steven A Julious, Joanne C Rothwell, et al.
Trials|June 14, 2017
Choosing the target difference ('effect size') for a randomised controlled trial - DELTA<sup>2</sup> guidance protocolJonathan A Cook, Steven A Julious, William Sones, et al.
Trials|October 26, 2019
Correction to: Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA2 guidanceWilliam Sones, Steven A Julious, Joanne C Rothwell, et al.
Journal of Clinical Epidemiology|April 26, 2023
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trialsDaniela R Junqueira, Liliane Zorzela, Susan Golder, et al.
Health Technology Assessment (Winchester, England)|December 23, 2016
PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term - a cluster randomised controlled trial and economic evaluationSteven A Julious, Michelle J Horspool, Sarah Davis, et al.
BMJ (Clinical Research Ed.)|April 24, 2023
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trialsDaniela R Junqueira, Liliane Zorzela, Susan Golder, et al.
BMJ Open|May 21, 2025
Mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: MissionEB protocol for a randomised, double-blinded, placebo-controlled, two-centre, crossover trial with an internal phase I dose de-escalation phase and open-label extensionMaria L Bageta, Pablo López-Balboa, Munyaradzi Dimairo, et al.
BMC Medicine|November 17, 2018
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive designMunyaradzi Dimairo, Elizabeth Coates, Philip Pallmann, et al.
Trials|June 18, 2020
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
BMC Public Health|June 7, 2014
A theory-based online health behaviour intervention for new university students (U@Uni): results from a randomised controlled trialTracy Epton, Paul Norman, Aba-Sah Dadzie, et al.
Trials|October 12, 2018
Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA<sup>2</sup> guidanceWilliam Sones, Steven A Julious, Joanne C Rothwell, et al.
Trials|June 14, 2017
Choosing the target difference ('effect size') for a randomised controlled trial - DELTA<sup>2</sup> guidance protocolJonathan A Cook, Steven A Julious, William Sones, et al.
Trials|October 26, 2019
Correction to: Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA2 guidanceWilliam Sones, Steven A Julious, Joanne C Rothwell, et al.
Journal of Clinical Epidemiology|April 26, 2023
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trialsDaniela R Junqueira, Liliane Zorzela, Susan Golder, et al.
Health Technology Assessment (Winchester, England)|December 23, 2016
PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term - a cluster randomised controlled trial and economic evaluationSteven A Julious, Michelle J Horspool, Sarah Davis, et al.
BMJ (Clinical Research Ed.)|April 24, 2023
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trialsDaniela R Junqueira, Liliane Zorzela, Susan Golder, et al.
BMJ Open|May 21, 2025
Mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: MissionEB protocol for a randomised, double-blinded, placebo-controlled, two-centre, crossover trial with an internal phase I dose de-escalation phase and open-label extensionMaria L Bageta, Pablo López-Balboa, Munyaradzi Dimairo, et al.
BMC Medicine|November 17, 2018
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive designMunyaradzi Dimairo, Elizabeth Coates, Philip Pallmann, et al.
Trials|June 18, 2020
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
Pageof 9